Induction of NFkappa B is required for efficient expression of latent
Induction of NFkappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol 2007, 81:6043-6056. 29. West MJ, Lowe AD, Karn J: Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol 2001, 75:8524-8537. 30. Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, Kutsch O: Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol 2009, 83:3078-3093. 31. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS: Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989, 86:2365-2368. 32. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB: Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989, 86:5974-5978. 33. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM: NFkappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28506461 II. Mol Cell 2001, 8:327-337. 34. Marks PA, Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007, 25:84-90. 35. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM: A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 2009, 83:4749-4756.van der Sluis et al. Retrovirology 2011, 8:73 http://www.retrovirology.com/content/8/1/Page 12 of36. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP: Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010, 84:5958-5974. 37. Fernandez G, Zeichner SL: Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J 2010, 7:266. 38. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V, Veithen E, Cherrier T, Avettand V, Poutrel S, Piette J, de Launoit Y, Moutschen M, Burny A, Rouzioux C, de Wit S, Herbein G, Rohr O, Collette Y, Lambotte O, Clumeck N, van Lint C: Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009, 4:e6093. 39. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, Greene WC: Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004, 279:42008-42017. 40. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC: NFkappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006, 25:139-149. 41. Yu S, Cui K, Jothi R, Zhao DM, Jing X, Zhao K, Xue HH: GABP controls a critical transcription regulatory module that is essential for maintenance and differentiation of hematopoietic stem/progenitor cells. Blood 2011, 117:2166-2178. 42. Butera ST, Perez VL, Wu BY, Nabel GJ, Folks TM: Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J Virol 1991, 65:4645-4653. 43. Clouse KA, Powell D, Washington I, Poli G, Abamectin B1a chemical information Strebel K, Farrar W, Barstad P, Kovacs J, Fauci AS, Folks TM: Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 1989, 142:4.